MarketVIEW: Hepatitis A vaccines (Emerging/ROW)

MarketVIEW: Hepatitis A vaccines (Emerging/ROW) Add to your bookmarks!

$ 8 995 - July 2012 - by VacZine Analytics Group Of Assay Advantage Ltd - 65

Summary

Table of Contents

View Report

Search Inside

Industry

Drug and Medication

Keywords

Hepatitis A Vaccine
Vaccine

Hepatitis A (HAV) produces a self-limiting liver disease which can produce a range of symptoms such as nausea, anorexia, fever, malaise or abdominal pain. Unlike Hepatitis B and C viruses it does not cause a long term chronic infection although it can manifest itself as prolonged or relapsing disease for up to six months. The HAV virus is transmitted by person-to-person transmission through the fecal-oral route sometimes in outbreaks to due ingestion of contaminated food. Many countries in Africa, LATAM and SE Asia have high or intermediate endemnicity for HAV.

The Hepatitis A vaccine is highly effective at preventing HAV infection and is now recommended for all children at age 1 year in the United States and other selected countries which have added the vaccine as part of a national immunization program (NIP). The HAV vaccine is also widely used in the travelling population to high or intermediate endemic countries.

This MarketVIEW product is a comprehensive commercial opportunity assessment which forecasts the potential (value/volume) of HAV vaccines in 35 countries in the "Emerging" or Rest of World region (ROW) to 2030. The model takes into account expected new NIPs, probable "catch-up" campaigns and expansion of private sector use in selected age groups. A detailed executive presentation is also included outlining all model outputs, assumptions and a country-by-country review of epidemiological dynamics and vaccination policy.

THIS PRODUCT IS A EXECUTIVE PRESENTATION + 1 MODEL

Contents – Executive presentation (MS PowerPoint based)
Author’s note
Executive summary
Commercial model – key outputs
HAV monovalent vaccine(s): available market (€ 000s) to 2030
HAV monovalent vaccine(s): available volume (€ 000s) to 2030
HAV monovalent vaccine(s): BRIC-MT markets (€ 000s) to 2030
HAV monovalent vaccine(s): BRIC-MT volume (000s) to 2030
HAV monovalent vaccine(s): available market(s) (€ 000s) to 2030
Hepatitis A virus: Review of current epidemiology
Global epidemiology: seroprevalence
Global epidemiology: seroprevalence (cont..)
Global epidemiology: incidence
US: incidence
Europe: incidence
5EU overview: incidence
Other high-income countries: incidence
Trends in incidence rates (low endemicity countries)
BRIC-M: incidence
Other LATAM: epidemiology
Southeast Asia overview
Hong Kong
Singapore
Taiwan
Malaysia
Philippines
Thailand
South Korea
Mongolia
Nepal
HAV epidemiology summary
Hepatitis A virus vaccines: Key model assumptions
Populations modelled
Overview of modeling strategy: new infant NIPs
Overview of modeling strategy: private adult segment
Overview of modeling strategy: at risk population
National HAV vaccine policies
Populations modelled: at risk population
Commercial model assumptions: Infant, public
Commercial model assumptions: Infant, public (cont..)
Bibliography
Disclaimer
About VacZine Analytics
PAGES: 65 MS PowerPoint slides, fully referenced/sourced. Available in .pdf form
Contents – Vaccine demand model(s) (MS Excel-based)
Title sheet
Notes
CHARTS – VALUE (total)
CHARTS – VOLUME (total)
WPR summary
Country value summary (Total)
Public vs private value summary
Value adult (priv)
Value infant (priv)
Value preschool (priv)
Value infant (pub)
Value adult (pub)
Global price summary
Volume adult (priv)
Volume infant (priv)
Volume preschool (priv)
Volume infant (pub)
Volume adult (pub)
Country worksheets
China (infants)
S Korea (infants)
Israel (infants)
Australia (infants)
Argentina (infants)
Panama (infants)
Paraguay (infants)
Uruguay (infants)
Taiwan (infants)
Russia (infants)
Kazakhstan (infants)
India (infants)
Ukraine (infants)
Brazil (infants)
Turkey (infants)
Mexico (infants)
Peru (infants)
Venezuela (infants)
Columbia (infants)
Chile (infants)
Guatemala (infants)
Saudi Arabia (infants)
Other Middle East (infants)
Belarus (infants)
Hong Kong (infants)
Malaysia (infants)
Thailand (infants)
Vietnam (infants)
Nepal (infants)
Pakistan (infants)
Philippines (infants)
Mongolia (infants)
Pakistan (infants)
Pakistan (infants)
Pakistan (infants)
Japan (infants)
Sheets repeated for adults, preschoolers
Population databases
Scenarios
“at risk” populations
Urban populations
% private
HBV coverage: case studies
Epidemiology
Income groups
World Population
Back page
WORKSHEETS = 110

Drug And Medication Industry : Latest Reports

Vaccines - Global Markets Package

$ 24 060
Industry report
May 2013
by Global Research & Data Services

This market research report package offers a perspective on the actual market situation, trends and future outlook for vaccines in different countries around the world. The studies provide essential market ...

Infertility Drugs And Devices Market - Global Industry Analysis, Size, Share And Forecast, 2010 - 2017

$ 4 395
Industry report
November 2013
by Transparency Market Research

This report is an effort to identify factors, which will be the driving force for the infertility drugs and devices market and sub-markets in the next few years. The report provides an extensive analysis ...

Triple Analysis: Angiogenesis, Cancer Vaccines and Peptides

$ 5 175
Industry report
March 2013
by Bioseeker

This triple analysis focuses on cancer drug development strategies by the two mechanism/target/effect areas of Angiogenesis and Cancer Vaccines and by the compound strategy of Peptides. Each of these three ...

Triple Analysis: Angiogenesis, Cancer Vacc ...

March 2013 $ 5 175

Triple Analysis: Angiogenesis, Cancer Vacc ...

March 2013 $ 5 175

Triple Analysis: Apoptosis, Angiogenesis A ...

March 2013 $ 5 175

Triple Analysis: Apoptosis, Cancer Vaccine ...

March 2013 $ 5 175

Triple Analysis: Apoptosis, Cancer Vaccine ...

March 2013 $ 5 175

Triple Analysis: Apoptosis, Cancer Vaccine ...

March 2013 $ 5 175

Triple Analysis: Breast Cancer, Angiogenes ...

March 2013 $ 5 175

Drug And Medication Industry : Latest Downloads

Drug and Medication Industry Analysis

Industry report
April 2013
53 pages

... Use internally as part of a monthly cleansing regimen for gi health antibiotic, anti-inflammatory, antibacterial, antifungal, antioxidant, anti-parasitic, antiviral, disinfectant candida cleanse ...

Drug and Medication Market Brief

Industry report
April 2013
18 pages

... Antiosteoporosic drugs - casula m, filippi a, flacco e, gambera m, manzoli l, menditto e, orlando v, piccinelli r, tragni e, catapano a. Assessment and potential determinats of compliance and persistence to anti ...

Drug and Medication : Innovation and Technology Trends

Industry report
April 2013
12 pages

... Clinical regulatory toxicology phase i clinical phase ii clinical diabetes inflammation oncology (non-cytotoxic) anti-infectives clotting disorders obesity cns nce pipeline nce pipeline tyrosine-tzd, non ...